Dalma Hosszú
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dalma Hosszú has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- András Inotai
Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary
4 shared publications - Donald C. Lo
European Infrastructure for Translational Medicine (EATRIS), Amsterdam, The Netherlands
4 shared publications - George Dennis Obeng
Syreon Research Africa, Accra, Ghana
4 shared publications - Helene G. van der Meer
ZonMw, Den Haag, The Netherlands
4 shared publications - Kristóf Gyöngyösi
Syreon Research Institute, Budapest, Hungary
4 shared publications - Marcell Csanádi
Syreon Research Institute, Budapest, Hungary
4 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by ScienceOpen
Perceived impact and actionability of barriers to drug repurposing: Insights from a multi-stakeholder policy survey
- 12 August 2026
- Published by ScienceOpen
Open AccessPerceived impact and actionability of barriers to drug repurposing: Insights from a multi-stakeholder policy survey
- Open Access
- 14 May 2026
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (3)
Variation in use of PROMs and geographical distribution in clinical trials of selected hematological diseases in Europe
- 14 May 2026
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (3)
Open AccessVariation in use of PROMs and geographical distribution in clinical trials of selected hematological diseases in Europe
- Open Access
- 20 April 2026
- Published by ScienceOpen
From Pain to Patient Preferences: Patient Engagement in Early HTA for Repurposing Losartan in Osteogenesis Imperfecta
- 20 April 2026
- Published by ScienceOpen
Open AccessFrom Pain to Patient Preferences: Patient Engagement in Early HTA for Repurposing Losartan in Osteogenesis Imperfecta
- Open Access
- 26 March 2026
- Published by Elsevier in Health Policy OPEN
- Vol. 10, 100168
Policy barriers to drug repurposing in Europe: different stakeholder perspectives identified during survey-based shortlisting of key challenges
- 26 March 2026
- Published by Elsevier in Health Policy OPEN
- Vol. 10, 100168
Open AccessPolicy barriers to drug repurposing in Europe: different stakeholder perspectives identified during survey-based shortlisting of key challenges
- Open Access
- 1 January 2026
- Published by ScienceOpen
Perceived impact and actionability of barriers to drug repurposing: Insights from a multi-stakeholder policy survey
- 1 January 2026
- Published by ScienceOpen
Open AccessPerceived impact and actionability of barriers to drug repurposing: Insights from a multi-stakeholder policy survey
- Open Access
- 6 November 2025
- Published by Wiley in British Journal of Pharmacology
- Vol. 183 (2) , 219-233
The eyes of the beholder: Perceived barriers to successful drug repurposing
Despite tremendous advances in new drug development over recent decades, the medical needs of an ever increasing and ageing global population are still significantly unmet. Drug repurposing (DR)—finding new therapeutic uses for existing medicinal substances and products—offers a promising strategy by potentially reducing development time, costs and risk. However, currently, significant hurdles restrict broader application of DR. This study was conducted within the European Commission funded REMEDi4ALL consortium to systematically identify and analyse the key policy obstacles perceived to be hindering the success of DR. A systematic literature review was conducted using PubMed and Embase, supplemented by grey literature searches and expert interviews within the consortium. The extracted data underwent thematic analysis. A barrier tree was developed and validated through five workshops with 80 experts from seven stakeholder groups. From 4059 hits, 192 were included for data extraction, resulting in the identification of 33 key barriers grouped into nine main themes: perception of off‐patent medicines, business case for on‐patent DR, business case for off‐patent DR, non‐industry‐funded DR, ecosystem for non‐profit or small and medium‐sized enterprise‐driven repurposing, market authorisation, exclusivity rights, health technology assessment and pricing. This comprehensive analysis provides a foundation for prioritizing the main areas for future interventions. Surprisingly, there were considerable differences in how different stakeholders perceived the importance of a number of key barriers. Such multidimensional aspects of DR barriers will need to inform future development of actionable policy recommendations to enhance the DR ecosystem and facilitate broader access to repurposed medicines.
- 6 November 2025
- Published by Wiley in British Journal of Pharmacology
- Vol. 183 (2) , 219-233
Open AccessThe eyes of the beholder: Perceived barriers to successful drug repurposing
Despite tremendous advances in new drug development over recent decades, the medical needs of an ever increasing and ageing global population are still significantly unmet. Drug repurposing (DR)—finding new therapeutic uses for existing medicinal substances and products—offers a promising strategy by potentially reducing development time, costs and risk. However, currently, significant hurdles restrict broader application of DR. This study was conducted within the European Commission funded REMEDi4ALL consortium to systematically identify and analyse the key policy obstacles perceived to be hindering the success of DR. A systematic literature review was conducted using PubMed and Embase, supplemented by grey literature searches and expert interviews within the consortium. The extracted data underwent thematic analysis. A barrier tree was developed and validated through five workshops with 80 experts from seven stakeholder groups. From 4059 hits, 192 were included for data extraction, resulting in the identification of 33 key barriers grouped into nine main themes: perception of off‐patent medicines, business case for on‐patent DR, business case for off‐patent DR, non‐industry‐funded DR, ecosystem for non‐profit or small and medium‐sized enterprise‐driven repurposing, market authorisation, exclusivity rights, health technology assessment and pricing. This comprehensive analysis provides a foundation for prioritizing the main areas for future interventions. Surprisingly, there were considerable differences in how different stakeholders perceived the importance of a number of key barriers. Such multidimensional aspects of DR barriers will need to inform future development of actionable policy recommendations to enhance the DR ecosystem and facilitate broader access to repurposed medicines.
- Open Access
- 1 January 2024
- Published by Haemnet Ltd in The Journal of Haemophilia Practice
- Vol. 11 (1) , 99-107
System change in practice: A report from the EHC Think Tank workstreams on Access Equity and Future Care Pathways
Introduction: The European Haemophilia Consortium (EHC) Think Tank was established as a platform for system change to ensure the healthcare ecosystem remains effective and relevant for people with bleeding disorders and other rare diseases. Operating alongside traditional advocacy initiatives, it comprised a series of thematic workstreams in which multiple stakeholders explored and co-designed potential solutions for specific aspects of the healthcare system. This final report from the workstreams on Access Equity and Future Care Pathways summarises recommendations for system change and the actions needed to achieve critical goals. Methodology/Process: In a three-phase Discovery-Strategy-Innovation process, workstream participants explored vital challenges to the system in which they were working, mapped the system to identify enablers and constraints to progress, and determined leverage points to explore strategies for change before co-creating a set of recommendations for action. Results: Participants in the Access Equity workstream identified a need for evidence-based narratives to drive policy change by effectively reaching and engaging target audiences. Fostering trust among stakeholders, supported by ‘open, active listening’, was seen as essential for progress towards access equity, as was promoting value-based frameworks by ensuring that decision-makers understand the broader impact of progress in access equity for health improvement. Participants in the Future Care Pathways workstream focused on digitalisation, patient preferences and financial incentives as drivers of progress towards creating seamless, personalised care pathways that can be measured effectively. Recommendations included fostering a coordination mindset and culture, encouraging patients to take ownership of their digital healthcare records, and enabling personalised care plans through flexibility in care pathways. Conclusions: Among the co-created, innovative strategies and recommendations proposed by workstream participants, key elements to support system change in Access Equity and Future Care Pathways, respectively, include demonstrating value through evidence-based narratives and integrating digital technology into care pathways to enhance patient-centred care. Appropriate capacity-building for all stakeholders, particularly healthcare professionals (HCPs) and patients, will be essential for the success of these initiatives.
- 1 January 2024
- Published by Haemnet Ltd in The Journal of Haemophilia Practice
- Vol. 11 (1) , 99-107
Open AccessSystem change in practice: A report from the EHC Think Tank workstreams on Access Equity and Future Care Pathways
Introduction: The European Haemophilia Consortium (EHC) Think Tank was established as a platform for system change to ensure the healthcare ecosystem remains effective and relevant for people with bleeding disorders and other rare diseases. Operating alongside traditional advocacy initiatives, it comprised a series of thematic workstreams in which multiple stakeholders explored and co-designed potential solutions for specific aspects of the healthcare system. This final report from the workstreams on Access Equity and Future Care Pathways summarises recommendations for system change and the actions needed to achieve critical goals. Methodology/Process: In a three-phase Discovery-Strategy-Innovation process, workstream participants explored vital challenges to the system in which they were working, mapped the system to identify enablers and constraints to progress, and determined leverage points to explore strategies for change before co-creating a set of recommendations for action. Results: Participants in the Access Equity workstream identified a need for evidence-based narratives to drive policy change by effectively reaching and engaging target audiences. Fostering trust among stakeholders, supported by ‘open, active listening’, was seen as essential for progress towards access equity, as was promoting value-based frameworks by ensuring that decision-makers understand the broader impact of progress in access equity for health improvement. Participants in the Future Care Pathways workstream focused on digitalisation, patient preferences and financial incentives as drivers of progress towards creating seamless, personalised care pathways that can be measured effectively. Recommendations included fostering a coordination mindset and culture, encouraging patients to take ownership of their digital healthcare records, and enabling personalised care plans through flexibility in care pathways. Conclusions: Among the co-created, innovative strategies and recommendations proposed by workstream participants, key elements to support system change in Access Equity and Future Care Pathways, respectively, include demonstrating value through evidence-based narratives and integrating digital technology into care pathways to enhance patient-centred care. Appropriate capacity-building for all stakeholders, particularly healthcare professionals (HCPs) and patients, will be essential for the success of these initiatives.
- Open Access
- 1 January 2023
- Published by Haemnet Ltd in The Journal of Haemophilia Practice
- Vol. 10 (1) , 155-163
Short- and longer-term goals for change – A report from the 2nd workshops of the EHC Think Tank Workstreams on Access Equity and Future Care Pathways
Introduction: The second series of workshops for the EHC Think Tank Workstreams on Access Equity and Future Care Pathways involved working towards consensus on addressing challenges to progress around achieving equitable access to care and shaping rare disease care pathways that meet patient needs while remaining practicable and affordable to healthcare providers. This report summarises workshop outcomes from these two workstreams, in which stakeholder participants identified a ‘guiding star’ determining the direction of ongoing focus, defined achievable ‘near star’ milestones, and enablers and constraints to achieving these. Guiding Stars: The Access Equity Workstream proposed focusing on developing a healthcare system that enables patients to benefit from care and treatment fairly and impartially. The Future Care Pathways Workstream agreed that their focus would be on developing care pathways that provide the right intervention at the right time by the right healthcare professional in the right formats with a variety of delivery methods to suit the person. Near Stars: For the Access Equity Workstream, changes in narrative and behaviour were the achievable milestones that the group agreed to prioritise. Greater stakeholder collaboration and consistent data collection and use will be important enablers for change. Participants proposed greater emphasis on investment and value (instead of cost and return) and a change of mindset from ‘fixing the patient’ to achieving a healthy life through early intervention and preventing comorbidities. However, lack of clarity over what constitutes ‘value’ and around stakeholders' responsibilities, limited outcome measures and resistance to change may constrain progress. A near star for the Future Care Pathways workstream was the development of seamless, personalised care pathways with integrated digital and AI-based technologies to enable real-time measurement of pathway effectiveness. Participants felt that understanding and respecting patient behaviour and the nudges and incentives needed to promote pathway acceptance will be important. As in the Access Equity Workstream, they recognised the role of routine, standardised data collection for measuring outcomes, sharing information and informing decision-making. They predicted that building trust between stakeholder groups (including patients, healthcare providers, academic and life science companies) and using patient networks and advocates effectively would enable collaboration and ensure that patient needs and insights are acted upon. However, financial and legal aspects, inadequate implementation of technological infrastructure, limited systems integration, and lack of stakeholder time, effort and energy are all potential constraints that will need to be addressed.
- 1 January 2023
- Published by Haemnet Ltd in The Journal of Haemophilia Practice
- Vol. 10 (1) , 155-163
Open AccessShort- and longer-term goals for change – A report from the 2nd workshops of the EHC Think Tank Workstreams on Access Equity and Future Care Pathways
Introduction: The second series of workshops for the EHC Think Tank Workstreams on Access Equity and Future Care Pathways involved working towards consensus on addressing challenges to progress around achieving equitable access to care and shaping rare disease care pathways that meet patient needs while remaining practicable and affordable to healthcare providers. This report summarises workshop outcomes from these two workstreams, in which stakeholder participants identified a ‘guiding star’ determining the direction of ongoing focus, defined achievable ‘near star’ milestones, and enablers and constraints to achieving these. Guiding Stars: The Access Equity Workstream proposed focusing on developing a healthcare system that enables patients to benefit from care and treatment fairly and impartially. The Future Care Pathways Workstream agreed that their focus would be on developing care pathways that provide the right intervention at the right time by the right healthcare professional in the right formats with a variety of delivery methods to suit the person. Near Stars: For the Access Equity Workstream, changes in narrative and behaviour were the achievable milestones that the group agreed to prioritise. Greater stakeholder collaboration and consistent data collection and use will be important enablers for change. Participants proposed greater emphasis on investment and value (instead of cost and return) and a change of mindset from ‘fixing the patient’ to achieving a healthy life through early intervention and preventing comorbidities. However, lack of clarity over what constitutes ‘value’ and around stakeholders' responsibilities, limited outcome measures and resistance to change may constrain progress. A near star for the Future Care Pathways workstream was the development of seamless, personalised care pathways with integrated digital and AI-based technologies to enable real-time measurement of pathway effectiveness. Participants felt that understanding and respecting patient behaviour and the nudges and incentives needed to promote pathway acceptance will be important. As in the Access Equity Workstream, they recognised the role of routine, standardised data collection for measuring outcomes, sharing information and informing decision-making. They predicted that building trust between stakeholder groups (including patients, healthcare providers, academic and life science companies) and using patient networks and advocates effectively would enable collaboration and ensure that patient needs and insights are acted upon. However, financial and legal aspects, inadequate implementation of technological infrastructure, limited systems integration, and lack of stakeholder time, effort and energy are all potential constraints that will need to be addressed.